TrovaGene, Inc. (NASDAQ:TROV)’s share price shot up NaN during trading on Wednesday . The stock traded as high as $0.78 and last traded at $0.00. 1,516,772 shares were traded during trading, an increase of Infinity from the average session volume of 0 shares.
Several brokerages have commented on TROV. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a research report on Thursday, August 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of TrovaGene in a research report on Tuesday, August 8th.
Several hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP lifted its stake in shares of TrovaGene by 2,781.0% during the 2nd quarter. Susquehanna International Group LLP now owns 138,031 shares of the medical research company’s stock worth $174,000 after purchasing an additional 133,240 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of TrovaGene by 1,079.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 278,186 shares of the medical research company’s stock worth $351,000 after purchasing an additional 254,601 shares during the last quarter. LMR Partners LLP purchased a new stake in shares of TrovaGene during the 2nd quarter worth $151,000. Finally, KCG Holdings Inc. lifted its stake in shares of TrovaGene by 560.1% during the 1st quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock worth $242,000 after purchasing an additional 178,440 shares during the last quarter. Institutional investors and hedge funds own 8.91% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “TrovaGene, Inc. (TROV) Shares Up NaN” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/11/01/trovagene-inc-trov-shares-up-nan.html.
TrovaGene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.